A Phase II, Multicenter, Single Arm Study to Determine the Efficacy and Safety of Low Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab as Primary Therapy in Elderly Untreated Patients (>/=65 Years Old) With Chronic Lymphocytic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate (according to National Cancer Institute - Working Group [NCI-WG] guidelines)
5 years
No
Clinical Trials
Study Director
Hoffmann-La Roche
Israel: Ministry of Health, Pharmaceutical Administration
ML25464
NCT01263704
July 2011
June 2016
Name | Location |
---|